← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Altor Bioscience. Llc
Miramar, FL
$18,414,026
Total funding
12
Grants
Funding over time
peak $2.5M · FY2006–19$5M$3.8M$2.5M$1.3M$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$18,414,026 · 12
By mechanism
R44$17,095,674 · 6
R43$1,318,352 · 6
Investigators at Altor Bioscience. Llc
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
Tissue Factor Antagonists for ALI/ARDS$1,062,358
R44 · FY2011 · HL
Tissue Factor Antagonists for ALI/ARDS$1,062,358
R44 · FY2013 · HL
Tissue Factor Antagonists for ALI/ARDS$1,062,358
R44 · FY2012 · HL
Tissue Factor Antagonists: Acute Lung Injury/ Acute Respiratory Distress Syndrome$1,042,563
R44 · FY2007 · HL
Tissue Factor Antagonists for ALI/ARDS$1,037,283
R44 · FY2006 · HL
Bifunctional T cell receptor based immunotherapeutics$1,000,000
R44 · FY2009 · CA
Novel IL-15 Superagonist Therapy for Bladder Cancer$999,919
R44 · FY2017 · CA
Novel IL-15 Superagonist Therapy for Bladder Cancer$999,919
R44 · FY2018 · CA
Novel IL-15 Superagonist Therapy for Bladder Cancer$999,919
R44 · FY2019 · CA
Bifunctional T cell receptor based immunotherapeutics$990,016
R44 · FY2010 · CA
Bifunctional T cell receptor based immunotherapeutics$979,275
R44 · FY2011 · CA
Combination Immunotherapy of a Novel Superagonist IL-15 Complex and Anti-CD20 Antibody for Indolent Non-Hodgkin Lymphoma$966,343
R44 · FY2016 · CA
Combination Immunotherapy of a Novel Superagonist IL-15 Complex and Anti-CD20 Antibody for Indolent Non-Hodgkin Lymphoma$961,768
R44 · FY2015 · CA
IL-15 Superagonist Complex as an Immunotherapeutic for Multiple Myeloma$750,000
R44 · FY2014 · CA
IL-15 Superagonist Complex as an Immunotherapeutic for Multiple Myeloma$750,000
R44 · FY2015 · CA
Transgenic Plant Technology for Producing Therapeutic Recombinant Antibodies$706,899
R44 · FY2007 · CA
Novel IL-15 Superagonist Therapy for Bladder Cancer$598,323
R44 · FY2014 · CA
Novel IL-15 Superagonist Therapy for Bladder Cancer$598,323
R44 · FY2015 · CA
Transgenic Plant Technology for Producing Therapeutic Recombinant Antibodies$528,050
R44 · FY2006 · CA
CD20-targeted IL-15 immunotherapeutic for B-cell malignancies$257,303
R43 · FY2012 · CA